Sunlenca, Injektionslösung

7680683850012 CH-68385 Injektionslösung
Sunlenca, Injektionslösung
Sunlenca, Injektionslösung
Sunlenca, Injektionslösung
1 / 3
google

Article details

Package size
2
Selling units
2
Measure
Durchstechflasche(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
24/12/2025
Patient information leaflet
Français
24/12/2025
Patient information leaflet
Italien
24/12/2025
Summary of Product Characteristics
Allemand
24/12/2025
Summary of Product Characteristics
Français
24/12/2025
Summary of Product Characteristics
Italien
24/12/2025

Detailed composition

Substance Quantity Type Category
lenacapavirum
463.5 MG Substance Wirkstoff (Principe actif)
lenacapavirum natricum
- Substance WIZUS
macrogolum 300
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
aqua ad iniectabile
- Substance HNIDK
natrium
10.99 MG Substance HBESI

Reimbursement information

Public price
CHF 20360.15
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/11/2024

Authorization holder

Gilead Sciences Switzerland Sàrl

6300 Zug

Authorization information

Swissmedic authorization number
68385
Drug name
Sunlenca, Injektionslösung
Galenic form
LSINJ
ATC Code
J05AX31
Authorization status
Z
Dispensing category
A
First authorization
07/07/2023
Authorization expiration date
06/07/2028
IT Number
08.03.0.
Domain
Human medicine
Field of application
HIV-Infektion

Package details

Description (FR)
SUNLENCA sol inj 463.5 mg/1.5ml 2 flac 1.5 ml
Description (DE)
SUNLENCA Inj Lös 463.5 mg/1.5ml 2 Durchstf 1.5 ml
Market launch
07/07/2023
Narcotic (BTM)
No
Buy us a coffee Explore the data